MTNB Matinas BioPharma Holdings Inc
Price (delayed)
$0.595
Market cap
$3.03M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.98
Enterprise value
-$1.36M
Matinas BioPharma is a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care for patients in areas of significant unmet medical need. Company leadership has
Highlights
Matinas BioPharma Holdings's debt has decreased by 19% YoY and by 6% QoQ
The EPS has contracted by 9% from the previous quarter but it has grown by 6% YoY
Matinas BioPharma Holdings's revenue has plunged by 100% YoY
The gross profit has dropped by 100% year-on-year
Key stats
What are the main financial stats of MTNB
Market
Valuations
Earnings
Shares outstanding
5.09M
Market cap
$3.03M
Enterprise value
-$1.36M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.4
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$24.59M
Net income
-$24.25M
EBIT
-$24.33M
EBITDA
-$23.36M
Free cash flow
-$15.89M
Per share
Balance sheet
Liquidity
EPS
-$4.98
EPS diluted
-$4.98
Free cash flow per share
-$3.26
Book value per share
$1.49
Revenue per share
$0
TBVPS
$2.6
Total assets
$12.64M
Total liabilities
$5.05M
Debt
$2.89M
Equity
$7.59M
Working capital
$5.36M
Debt to equity
0.38
Current ratio
3.01
Quick ratio
2.75
Net debt/EBITDA
0.19
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-125.7%
Return on equity
-170.1%
Return on invested capital
-181.1%
Return on capital employed
-243.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MTNB stock price
How has the Matinas BioPharma Holdings stock price performed over time
Intraday
1.71%
1 week
-0.83%
1 month
-0.78%
1 year
-93.45%
YTD
16.67%
QTD
14.42%
Financial performance
How have Matinas BioPharma Holdings's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$24.59M
Net income
-$24.25M
Gross margin
N/A
Net margin
N/A
Matinas BioPharma Holdings's revenue has plunged by 100% YoY
The gross profit has dropped by 100% year-on-year
The company's net income fell by 15% QoQ and by 6% YoY
The operating income has contracted by 12% from the previous quarter and by 3.5% YoY
Growth
What is Matinas BioPharma Holdings's growth rate over time
Valuation
What is Matinas BioPharma Holdings stock price valuation
P/E
N/A
P/B
0.4
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has contracted by 9% from the previous quarter but it has grown by 6% YoY
The stock's price to book (P/B) is 86% less than its 5-year quarterly average of 2.9 and 79% less than its last 4 quarters average of 1.9
The company's equity has shrunk by 61% YoY and by 52% QoQ
Matinas BioPharma Holdings's revenue has plunged by 100% YoY
Efficiency
How efficient is Matinas BioPharma Holdings business performance
Matinas BioPharma Holdings's ROIC has plunged by 97% YoY and by 46% from the previous quarter
The ROE has dropped by 91% year-on-year and by 38% since the previous quarter
The return on assets has dropped by 74% year-on-year and by 33% since the previous quarter
Dividends
What is MTNB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MTNB.
Financial health
How did Matinas BioPharma Holdings financials performed over time
Matinas BioPharma Holdings's total assets is 150% higher than its total liabilities
Matinas BioPharma Holdings's total assets has decreased by 50% YoY and by 39% QoQ
MTNB's current ratio is down by 49% year-on-year and by 46% since the previous quarter
Matinas BioPharma Holdings's debt is 62% lower than its equity
The company's debt to equity has surged by 111% YoY and by 100% QoQ
The company's equity has shrunk by 61% YoY and by 52% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.